# Exparel vs Block for ACL Reconstruction

> **NCT06006624** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Rothman Institute Orthopaedics** · enrollment: 154 (estimated)

## Conditions studied

- ACL
- Postoperative Pain

## Interventions

- **DRUG:** Exparel 30 mL
- **DRUG:** 0.5% bupivacaine
- **DRUG:** Dexamethasone
- **DRUG:** iPACK block

## Key facts

- **NCT ID:** NCT06006624
- **Lead sponsor:** Rothman Institute Orthopaedics
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-08-21
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006624, "Exparel vs Block for ACL Reconstruction". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06006624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*